News Release 

US hydroxychloroquine, chloroquine, azithromycin outpatient prescriptions October 2019-March 2020

JAMA Internal Medicine

What The Study Did: How the prescription of hydroxychloroquine and chloroquine to outpatients has changed in the United States during the COVID-19 pandemic is examined in this study.

Authors: Daniel S. Budnitz, M.D., M.P.H., of the Centers for Disease Control and Prevention COVID-19 Response Team in Atlanta, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamainternmed.2020.2594)

Editor's Note: The article includes funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.2594?guestAccessKey=eeed444b-975c-4a8c-ab36-b7ada61bc7541&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070620

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.